---
title: Improve walking speed with vibrotactile
nct_id: NCT07308418
phase: NA
status: RECRUITING
sponsor: Magnes AG
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07308418"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07308418"
last_fetched: "2026-05-10T14:03:27.516Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking speed with vibrotactile

**Goal (in five words):** Improve walking speed with vibrotactile

**Official Title:** The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease

**Trial ID:** [NCT07308418](https://clinicaltrials.gov/study/NCT07308418)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Magnes AG
- **Target Enrollment:** 16 participants
- **Start Date:** 2026-01-10
- **Completion Date:** 2026-05
- **Conditions:** Parkinson's Disease (PD)
- **Interventions:** Vibrotactile feedback during walking
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to see whether gentle vibration cues can help people with Parkinson's walk faster at their usual pace, by improving step timing and cadence that often become slow or irregular. The approach uses wearable vibrotactile feedback during walking, delivering gentle rhythmic vibrations as an external sensory cue to boost gait timing; it is not a drug and does not change levodopa or other dopaminergic therapy, so participants stay on stable medication. The trial is looking for adults 18 and older with a medically confirmed Parkinson's diagnosis who can walk at least 200 meters, have had no change in dopaminergic meds for at least four weeks, and can understand German; people with atypical parkinsonism, sensory loss in the feet, other major conditions affecting walking, or significant cognitive impairment are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion criteria:

* A medically confirmed diagnosis of Parkinson's disease on the physiotherapy prescription.
* Stable medication for at least four weeks (no change in dopaminergic therapy).
* The ability to walk at least 200 metres without stopping.
* Minimum age: 18 years
* Sufficient knowledge of German to understand the study information and complete the questionnaires.
* Written informed consent form

Exclusion criteria:

* Atypical or secondary Parkinsonism
* Sensory disturbances in the feet (e.g. polyneuropathy).
* Other neurological, orthopaedic or internal medical conditions that significantly affect walking
* Cognitive impairments that interfere with understanding the study information or following instructions
```

## Locations (1)

- Magnes AG, Zurich, Canton of Zurich, Switzerland _(47.3667, 8.5500)_
  - Romina Willi — (CONTACT) — 0442234873 — research@magnes.ch

## Central Contacts

- Romina Willi — (CONTACT) — +41442234873 — research@magnes.ch

---

*Canonical: https://parkinsonspathways.com/trial/NCT07308418*  
*HTML version: https://parkinsonspathways.com/trial/NCT07308418*  
*Source data: https://clinicaltrials.gov/study/NCT07308418*